시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
동물 의료용 단클론항체 시장 분석과 예측 : 유형, 제품, 서비스, 기술, 용도, 최종 사용자, 프로세스, 기능(-2034년)
Monoclonal Antibodies In Veterinary Health Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Process, Functionality
상품코드 : 1740688
리서치사 : Global Insight Services LLC
발행일 : 2025년 06월
페이지 정보 : 영문 393 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,587,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,974,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,360,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

동물 의료용 단클론항체 시장은 2024년 8억 1,840만 달러로 평가되었고, 2034년에는 40억 5,600만 달러에 이르고, 약 17.4%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. 동물 의료용 단클론항체는 특정 병원체와 질병을 표적으로 하는 동물 건강을 위해 설계된 바이오 의약품을 포함합니다. 이 항체는 가축과 동반 동물의 전반적인 병리를 정확하게 치료하고 치료 효과와 안전성을 높입니다.

시장 개요 :

동물 의료용 단클론항체 시장은 주로 인류 공통 감염의 유행과 고도의 동물용 치료제에 대한 수요 증가에 의해 강력한 성장을 이루고 있습니다. 반려동물 부문은 반려동물 소유가 증가하고 반려동물 건강에 대한 인식이 높아지면서 선도적인 시장 부문으로 부상하고 있습니다. 진보가 치료 효과를 높이고 있는 것에 기인하고 있습니다. 이와 병행해, 축산 분야도 기세를 늘리고 있습니다. 말 건강과 같은 새로운 하위 세그먼트는 특히 특정 말 질병을 표적으로 하는 단일 클론 항체의 혁신으로 잠재력을 발휘하고 있습니다. 이러한 개발에 의해 시장 발전이 진행되어, 향후의 성장이 기대되는 것과 동시에, 동물 의료용 단클론항체 치료의 영역이 확대될 것으로 예측됩니다.

시장 세분화
유형 마우스, 키메라, 인간화, 재조합
제품 치료용 mAb, 진단용 mAb, 예방용 mAb, 바이오시밀러, 결합형 mAb
서비스 연구개발, 제조, 임상시험, 규제준수, 품질보증
기술 하이 브리 도마 기술, 파지 디스플레이, 트랜스 제닉 마우스, 단일 B 세포
용도 감염, 암,자가 면역 질환, 염증성 질환
최종 사용자 동물 병원, 연구 기관, 바이오 제약 기업, 동물 농장
형태 액체, 동결건조
배포 On-Premise, 클라우드 기반
프로세스 업스트림 프로세싱, 다운스트림 프로세싱
기능 중화, 옵소닌화, 항체 의존성 세포독성, 보체 활성화

주요 동향과 촉진요인 :

동물 의료용 단클론항체 시장은 몇 가지 주요 동향과 촉진요인에 의해 강력한 성장을 이루고 있습니다. 반려동물의 주인과 가축 생산자가 질병의 예방과 치료를 우선하기 때문에 동물의 건강과 복지에 대한 의식이 높아지고 있는 것이 주요 요인입니다. 이 때문에 단일클론항체를 포함한 고도의 동물용 치료제 수요가 급증하고 있습니다. 생명공학과 유전공학의 기술적 진보는 보다 효과적이고 표적화된 단일클론항체의 개발을 가능하게 합니다. 이러한 기술 혁신은 치료의 정확성과 효능을 향상시켜 다양한 동물 종에 대한 응용을 확대하고 있습니다. 또한, 동물 바이오로직에 대한 규제 당국의 승인과 지원은 이러한 제품의 안전성과 효능을 보장함으로써 시장 확대를 촉진하고 있습니다. 인수 공통 감염증 증가와 예방조치의 필요성이 단클론항체의 채택을 더욱 촉진하고 있습니다. 세계 무역과 여행이 증가함에 따라 동물과 인간 사이에 질병이 감염될 위험도 높아지고 첨단 건강 솔루션이 필요합니다. 또한 동물제약기업과 연구기관의 협력관계가 혁신을 촉진하고 제품개발을 가속화하고 있으며, 이 급성장시장에 유리한 기회를 창출하고 있습니다.

주요 억제요인과 도전 :

동물 의료용 단클론항체 시장에는 몇 가지 중대한 억제요인과 과제가 있습니다. 둘째, 엄격한 승인 프로세스가 제품의 입수를 늦추고 비용을 증가시키기 위해 규제상의 장애물이 까다로운 과제가됩니다. 인식이나 이해가 부족하고, 이것이 시장 침투의 방해가 되고 있습니다. 또한, 단클론항체는 복잡한 성질을 가지기 때문에 전문적인 보관이나 취급이 필요해, 동물 병원에 있어서는 물류상의 부담이 됩니다. 백신과 전통적인 의약품과 같은 대체 요법과 치료법과의 경쟁이 과제가 되고 있습니다.

목차

제1장 동물 의료용 단클론항체 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 동물 의료용 단클론항체 시장 전망

제5장 동물 의료용 단클론항체 시장 전략

제6장 동물 의료용 단클론항체 시장 규모

제7장 동물 의료용 단클론항체 시장 : 유형별

제8장 동물 의료용 단클론항체 시장 : 제품별

제9장 동물 의료용 단클론항체 시장 : 서비스별

제10장 동물 의료용 단클론항체 시장 : 기술별

제11장 동물 의료용 단클론항체 시장 : 용도별

제12장 동물 의료용 단클론항체 시장 : 최종 사용자별

제13장 동물 의료용 단클론항체 시장 : 형태별

제14장 동물 의료용 단클론항체 시장 : 전개별

제15장 동물 의료용 단클론항체 시장 : 프로세스별

제16장 동물 의료용 단클론항체 시장 : 기능별

제17장 동물 의료용 단클론항체 시장 : 지역별

제18장 경쟁 구도

제19장 기업 프로파일

SHW
영문 목차

영문목차

Monoclonal Antibodies In Veterinary Health Market is anticipated to expand from $818.4 million in 2024 to $4,056.0 million by 2034, growing at a CAGR of approximately 17.4%. The Monoclonal Antibodies in Veterinary Health Market encompasses biopharmaceuticals engineered for animal health, targeting specific pathogens and diseases. These antibodies offer precision in treating conditions across livestock and companion animals, enhancing therapeutic efficacy and safety. As zoonotic disease threats rise, demand for innovative veterinary biologics is increasing, driving advancements in production and regulatory frameworks.

Market Overview:

The Monoclonal Antibodies in Veterinary Health Market is experiencing robust growth, primarily driven by the increasing prevalence of zoonotic diseases and the rising demand for advanced veterinary therapeutics. The companion animals segment emerges as the leading market segment, fueled by the growing pet ownership and heightened awareness regarding pet health. This segment's dominance is attributed to the increasing adoption of monoclonal antibodies for treating chronic conditions such as arthritis and allergies in pets, alongside advancements in veterinary biotechnology enhancing therapeutic efficacy. In parallel, the livestock segment is gaining momentum, driven by the need for effective disease management in cattle and poultry to ensure food security and safety. Emerging sub-segments, such as equine health, are demonstrating potential, particularly with innovations in monoclonal antibodies targeting specific equine diseases. These developments are poised to broaden market applications, thereby driving future growth and expanding the reach of monoclonal antibody therapies in veterinary health.

Market Segmentation
TypeMurine, Chimeric, Humanized, Recombinant
ProductTherapeutic mAbs, Diagnostic mAbs, Prophylactic mAbs, Biosimilars, Conjugated mAbs
ServicesResearch and Development, Manufacturing, Clinical Trials, Regulatory Compliance, Quality Assurance
TechnologyHybridoma Technology, Phage Display, Transgenic Mice, Single B Cell
ApplicationInfectious Diseases, Cancer, Autoimmune Disorders, Inflammatory Diseases
End UserVeterinary Clinics, Research Institutes, Biopharmaceutical Companies, Animal Farms
FormLiquid, Lyophilized
DeploymentOn-Premise, Cloud-Based
ProcessUpstream Processing, Downstream Processing
FunctionalityNeutralization, Opsonization, Antibody-Dependent Cellular Cytotoxicity, Complement Activation

Geographical Overview:

The Monoclonal Antibodies in Veterinary Health Market is witnessing diverse growth patterns across various regions. North America leads the market, driven by advanced veterinary healthcare infrastructure and increasing pet ownership. The region's robust research and development capabilities further bolster its market position. Europe follows closely, with significant investments in veterinary biotechnology and a strong focus on animal welfare. The region's stringent regulatory framework ensures the safety and efficacy of monoclonal antibody treatments. In Asia Pacific, the market is expanding rapidly, fueled by a growing awareness of animal health and increasing livestock production. Governments in the region are investing in veterinary healthcare to enhance animal productivity and disease management. Latin America and the Middle East & Africa are emerging markets with promising potential. Latin America is experiencing a rise in veterinary healthcare investments, while the Middle East & Africa are recognizing the importance of monoclonal antibodies in improving animal health and supporting agricultural development.

Recent Developments:

The Monoclonal Antibodies in Veterinary Health Market has witnessed notable developments recently. Zoetis announced a strategic partnership with AbCellera to accelerate the discovery and development of monoclonal antibodies for veterinary applications, enhancing its pipeline for animal health solutions. Elanco Animal Health launched a novel monoclonal antibody product targeting canine atopic dermatitis, marking a significant innovation in veterinary dermatology. Boehringer Ingelheim expanded its research collaboration with a leading biotech firm to explore monoclonal antibody therapies for livestock, aiming to improve disease management in farm animals. Merck Animal Health reported successful clinical trial results for a monoclonal antibody treatment for bovine respiratory disease, which is expected to receive regulatory approval soon. The FDA updated its guidelines to streamline the approval process for monoclonal antibodies in veterinary medicine, potentially accelerating the introduction of new therapies to the market. These developments underscore the growing importance of monoclonal antibodies in advancing veterinary health care.

Key Companies:

Aratana Therapeutics, Kindred Bio, Zoetis, Boehringer Ingelheim Animal Health, Virbac, Elanco Animal Health, Ceva Sante Animale, Bayer Animal Health, Vetoquinol, Dechra Pharmaceuticals, Merck Animal Health, Phibro Animal Health, Hipra, Biogenesis Bago, Neogen Corporation, IDEXX Laboratories, Se Quent Scientific, Norbrook Laboratories, Kyoritsu Seiyaku, Huvepharma

Key Trends and Drivers:

The monoclonal antibodies in veterinary health market are experiencing robust growth, propelled by several key trends and drivers. Increasing awareness of animal health and welfare is a primary driver, as pet owners and livestock producers prioritize disease prevention and treatment. This has led to a surge in demand for advanced veterinary therapeutics, including monoclonal antibodies. Technological advancements in biotechnology and genetic engineering are enabling the development of more effective and targeted monoclonal antibodies. These innovations are enhancing the precision and efficacy of treatments, thereby broadening their application across various animal species. Additionally, regulatory approvals and support for veterinary biologics are facilitating market expansion by ensuring the safety and efficacy of these products. The rise in zoonotic diseases and the need for preventive measures is further driving the adoption of monoclonal antibodies. As global trade and travel increase, so does the risk of disease transmission between animals and humans, necessitating advanced health solutions. Furthermore, collaborations between veterinary pharmaceutical companies and research institutions are fostering innovation and accelerating product development, creating lucrative opportunities in this burgeoning market.

Key Restraints and Challenges:

The monoclonal antibodies in veterinary health market encounter several significant restraints and challenges. Firstly, the high cost of development and production of monoclonal antibodies limits their accessibility, particularly for smaller veterinary practices and in developing regions. Secondly, regulatory hurdles pose a formidable challenge, as stringent approval processes can delay product availability and increase costs. Thirdly, there is a lack of awareness and understanding among veterinarians and pet owners regarding the benefits and applications of monoclonal antibodies, which hampers market penetration. Additionally, the complex nature of monoclonal antibodies requires specialized storage and handling, which can be a logistical burden for veterinary clinics. Lastly, competition from alternative therapies and treatments, such as vaccines and traditional pharmaceuticals, presents a challenge, as these options are often more familiar and less costly. These factors collectively impede the market's growth potential and broader adoption.

Sources:

U.S. Department of Agriculture - Animal and Plant Health Inspection Service, European Medicines Agency - Veterinary Medicines, World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), International Federation for Animal Health (IFAH), American Veterinary Medical Association (AVMA), European Veterinary Medical Association (EVMA), United Nations Environment Programme - Veterinary Health, National Institutes of Health (NIH) - Veterinary Research, The Pirbright Institute, Royal Veterinary College - University of London, University of California, Davis - School of Veterinary Medicine, Cornell University College of Veterinary Medicine, International Veterinary Vaccinology Network, Federation of Veterinarians of Europe (FVE), International Conference on Veterinary Science and Medicine, World Veterinary Association Congress, Global Animal Health Conference, Veterinary Vaccines and Diagnostics Conference, International Symposium on Veterinary Epidemiology and Economics

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Monoclonal Antibodies In Veterinary Health Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Monoclonal Antibodies In Veterinary Health Market Outlook

5: Monoclonal Antibodies In Veterinary Health Market Strategy

6: Monoclonal Antibodies In Veterinary Health Market Size

7: Monoclonal Antibodies In Veterinary Health Market, by Type

8: Monoclonal Antibodies In Veterinary Health Market, by Product

9: Monoclonal Antibodies In Veterinary Health Market, by Services

10: Monoclonal Antibodies In Veterinary Health Market, by Technology

11: Monoclonal Antibodies In Veterinary Health Market, by Application

12: Monoclonal Antibodies In Veterinary Health Market, by End User

13: Monoclonal Antibodies In Veterinary Health Market, by Form

14: Monoclonal Antibodies In Veterinary Health Market, by Deployment

15: Monoclonal Antibodies In Veterinary Health Market, by Process

16: Monoclonal Antibodies In Veterinary Health Market, by Functionality

17: Monoclonal Antibodies In Veterinary Health Market, by Region

18: Competitive Landscape

19: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기